BJH - volume 11, issue Abstract Book BHS, february 2020
E. Linskens , S. Van Landeghem , K. Vandepoele PhD, K. Maes , I. Moors MD, J. Van Dorpe , C. Bonroy , K. Devreese , J. Philippé MD, PhD, B. Denys PharmD
BJH - volume 10, issue 6, october 2019
E. Van Valckenborgh PhD, M. Bakkus PhD, E. Boone PhD, A. Camboni MD, PhD, J-P. Defour PhD, B. Denys PharmD, H. Devos MD, L. Dewispelaere MD, G. Froyen PhD, A. Hébrant PhD, P. Heimann MD, PhD, P. Hermans MD, PhD, E. Heylen PhD, K. Jacobs PhD, F. Lambert MD, M. Le Mercier Apr, PhD, E. Lierman PhD, H. Louagie MD, PhD, B. Maes MD, PhD, M-B. Maes PhD, G. Martens MD, PhD, L. Michaux MD, PhD, F. Nollet PhD, H.A. Poirel MD, PhD, G. Raicevic PhD, P. Saussoy MD, PhD, T. Tousseyn MD, PhD, M. Van Den Bulcke PhD, P. Vandenberghe MD, PhD, K. Vandepoele PhD, P. Vannuffel PhD, T. Venken PhD, K. Vermeulen PhD
Molecular diagnostics have an increasing impact on diagnosis, risk stratification and targeted treatment in haemato-oncology. In the framework of a pilot study for the implementation of next-generation sequencing in the Belgian healthcare system, the Commission of Personalised Medicine was founded to give professional and evidence-based advice on the molecular analysis in haemato-oncology. This paper describes its recommendations for NGS analysis in myeloid malignancies. In addition, the minimally required set of genes that must be analysed is defined and algorithms for molecular workflow in myeloid malignancies are proposed.
(BELG J HEMATOL 2019;10(6):241–9)
Read moreBJH - volume 9, issue 6, november 2018
K. Imaeva , I. Moors MD, J. Van Dorpe , S. Verbeke , B. Denys PharmD
Blastic plasmacytoid dendritic cell neoplasm is a highly aggressive myeloid neoplasm with a high rate of central nervous system recurrence. We present a case to illustrate central nervous system involvement and possible treatment options.
(BELG J HEMATOL 2018;9(6):237–41)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
I. Moors MD, T. Kerre MD, PhD, B. Denys PharmD, M. Hofmans MD, K. Vandepoele PhD
BJH - volume 8, issue 2, march 2017
A-S. De Koninck PharmD, C. Dhooge MD, PhD, B. Denys PharmD, K. Vandepoele PhD, N. Van Roy PhD, M. Hofmans MD, J. Philippé MD, PhD
We describe a case of a four-year-old boy diagnosed with an Early T-cell Precursor Lymphoblastic Leukaemia. This type of leukaemia is recognised as a high-risk subgroup characterised by very early arrest in T-cell differentiation. Early T-cell Precursor Lymphoblastic Leukaemia cases have characteristic gene expression profiles, increased genomic instability and a distinct immature immunophenotype (CD1a–, CD8–, CD5+dim and positivity for at least one marker of stem cell or myeloid lineage). This type of leukaemia is associated with poor prognosis and a poor response to intensive chemotherapy, though this finding is still debated. Our patient displayed an inferior response to induction therapy. The main purpose of this report is to make Belgian physicians aware of this entity and its controversial prognostic significance.
(BELG J HEMATOL 2017;8(2):75–9)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
K. Vandepoele PhD, B. Denys PharmD
BJH - volume 8, issue Abstract Book BHS, february 2017
B. Denys PharmD, J. Van der Meulen , E. de Latter , S. Lefever , T. Rosseel , W. Steyaert , G. Vandercruyssen , I. Rottiers , D. Creytens , J. Van Dorpe , F. Speleman PhD, B. Poppe , N. Van Roy PhD, K. de Leeneer , K. Claes , K. Vandepoele PhD
Top
